CYAD-101

Phase 1Small molecule

CCelyad Oncology SA

CYAD-101 is one of 30 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Metastatic Colorectal CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Vectibix

Amgen

Phase 3

45 2

Braftovi

Pfizer

Phase 3

11 3

Cyramza

Eli Lilly

Phase 3

2 4

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

2 5

Fusilev

DDurata Therapeutics International BV (an Affiliate of Actavis, Inc.)

Phase 3

1 6

Cosela

PPharmacosmos A/S

Phase 3

1 7

Vatalanib

Novartis

Phase 3

2 8

PF-08634404

Pfizer

Phase 3

—9

Investigator's Choice Chemotherapy

Genmab

Phase 3

1 10

Brivanib Alaninate

GGynecologic Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2036

Phase 1Recruiting

Chimeric Antigen Receptor T-Cell

NCT03692429

Q2 2038

Phase 1Recruiting

Metastatic Colorectal Cancer

NCT04991948

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Recruiting·CCelyad Oncology SA·Phase 1·NCT04991948·34 enrolled

Chimeric Antigen Receptor T-cell1 trial

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Recruiting·CCelyad Oncology SA·Phase 1·NCT03692429·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CYAD-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CYAD-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CYAD-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celyad Oncology SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCelyad Oncology SA

CYAD-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2036

Q2 2038

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Chimeric Antigen Receptor T-cell1 trial

References

Drug Info

Quick Facts

Related News